Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01620229 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Hematopoietic/Lymphoid Cancer

Interventions

DRUG: brentuximab vedotin
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

Fred Hutchinson Cancer Center

Collaborators

[object Object]
[object Object]